Canadian contract manufacturer Patheon has teamed up with specialty
pharmaceutical firm Depomed to offer its clients a controlled
release formulation which can grant their drugs increased
bioavailability and less frequent dosing.
Despite its consolidation, the competitive consumable sector still
offers potential for rapid growth and better profits in the
biopharmaceutical industry, while contract bioprocessing services
will be increasingly in demand, according...
For the first time Merck has opened the doors of its
under-construction manufacturing plant in North Carolina to public
officials, boasting it will eventually contribute about two-thirds
of its annual live-virus vaccine production.
Newly-approved pearlescent pigments that can produce sparkly
metallic, satiny and shimmery finishes on drug coatings could be
used as one additional step in the fight against counterfeiting,
say its developers, EMD Chemicals - part...
India's potential to further boost its already dominant role in
global generics production, as well as an offshore location of
choice for contract manufacturing, presents an opportunity worth an
estimated $48bn (€38bn) in 2007,...
More problems at Patheon's Puerto Rican production facilities in
the third quarter of 2006 are expected to reduce the contract
manufacturer's earnings before interest, tax, depreciation and
amortisation (EBITDA) by more...
West Pharmaceutical Services has reported a huge surge in both
sales and profits for its second quarter, spurred on by the
increasing demand for injectable drugs as well as the lucrative
Exubera manufacturing contract, which helped...
Pharmaceutical excipients can have a profound impact on the release
profile of drugs, driving fine chemical companies to raise their
game since they realise their clients see excipients as more than
More and more drugmakers are turning to health care companies not
just for their drug delivery technologies but also for their
regulatory and manufacturing expertise, asking them to take their
product from early stages all the way...
After launching its flagship oral insulin spray in Ecuador last
December, Generex is finally gearing up to take on big pharma in
the global non-injectable insulin arena and has picked Cardinal
Health to help meet manufacturing demands.
Cardinal Health has taken the contract manufacturing crown after
being honoured with a prestigious award from Frost & Sullivan
in recognition of its ability to provide biopharma firms with a
high quality service, while still remaining...
Promed is due to start operations at its new research centre in
India, New Deli, this month, in a move that will bring the company
closer to becoming a global provider of drug development and supply
Having inked two new deals with large Indian contract research
organisations (CROs), US generics major Taro Pharmaceutical
Industries is beginning to shift some of its product R&D to
India in a bid to enhance its competitive position...